Other Golf Articles

Amgen NASDAQ: AMGN pharmaceutical company just announced positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.

Trial reached primary endpoint of Diminishing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an important regulator of osteoclasts the cells that break down bone). Denosumab is being investigated for its ability to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being researched for a variety of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to defer bone metastases and inhibit and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a global problem illness, which is growing in significance as the world population both increases and ages. The World Health Organization (WHO) has just identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this horrendous disease.

Amgen states that the economic burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed almost at the same time as the medications that assist in the treatment of the primary illness. The fact that information is available to help anticipate the potential effects and interactions drugs have with one another is outstanding.

There are several drugs that both, prevent and treat osteoporosis. Some medicines slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth can diminish the danger of broken bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.

prescription drug